Labat Africa (JSE:LAB) Beta: 0.3897 (As of Jun. 25, 2026)


What is Labat Africa Beta?

Labat Africa JSE:LAB +66.67% Beta is 0.3897 as of Jun. 25, 2026. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Labat Africa's Beta is 0.3897.


Labat Africa  (JSE:LAB) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Labat Africa Beta Related Terms


Labat Africa Beta Historical Data

* Premium members only.

The historical data trend for Labat Africa's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labat Africa Beta Chart

Labat Africa Annual Data
Trend Feb14 Feb15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 May23 May24
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 1.15 1.34 1.89 0.39

Labat Africa Semi-Annual Data
Aug15 Aug16 Feb17 Aug17 Feb18 Aug18 Feb19 Aug19 Feb20 Aug20 Feb21 Aug21 Feb22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.39 0.32 0.30 0.16

JSE:LAB vs ZTS, UTHR, VTRS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Labat Africa Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Labat Africa's Beta distribution charts can be found below:

* The bar in red indicates where Labat Africa's Beta falls into.



Labat Africa Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.3897 mean?
Labat Africa (JSE:LAB) has a Beta of 0.3897 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Labat Africa and its competitors.
Is Labat Africa's Beta too high?
Labat Africa's current Beta is 0.3897.
How does Labat Africa's Beta compare to ZTS and UTHR?
Labat Africa's Beta of 0.3897 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Labat Africa and its competitors. Labat Africa's current Beta is 0.3897. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.22, compared to a current price of R0.05 — trading 77.3% below its estimated fair value. The current Beta is 0.3897. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current Beta is 0.3897 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Labat Africa Business Description

Other Exchanges LAO:Germany
Address 75 Maude StreetSandown, The Leonardo 14th Floor, Sandown, Johannesburg, GT, ZAF, 1709
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.